[Skip to Content]
[Skip to Content Landing]
October 23, 1954

Streptococcal Infections

JAMA. 1954;156(8):800. doi:10.1001/jama.1954.02950080048026

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


The advent of the sulfonamides as therapeutic agents for the treatment of streptococcic infection dealt serious blows to fundamental studies of the biology, metabolism, and immunochemistry of the Streptococcus and to the natural history of diseases produced especially by beta hemolytic streptococci belonging to group A (Lancefield). Today many students graduate from medical schools without ever having seen a patient with erysipelas or scarlet fever. Fortunately for those who are interested in the biology of streptococci, there remain a number of investigators, such as Lancefield, Tillett, McCarty, Rammelkamp, Dingle, and others, who have an abiding interest in this field and who are continually advancing knowledge in it. Also it is fortunate that the section on microbiology of the New York Academy of Medicine decided that in 1953 a symposium should be held on streptococcic infections. The proceedings of this symposium, which cover the chemistry, metabolism, immunologic aspects, and the natural

First Page Preview View Large
First page PDF preview
First page PDF preview